Navigation Links
Teriparatide outperforms alendronate in treating steroid-induced osteoporosis
Date:10/28/2009

A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate. The findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Glucocorticoids are steroid hormones that are naturally produced in the body or synthetically created compounds (drugs) used to reduce inflammation. These steroid drugs are used to control inflammation in patients with such autoimmune diseases as rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease as well as inflammatory conditions such as asthma. Glucocorticoid-induced osteoporosis occurs when patients taking steroid medications such as prednisone, prednisolone, dexamethasone, and cortisone exhibit reduced bone mass and bone strength.

This 36-month, randomized, double-blind, controlled trial, led by Kenneth Saag, M.D., from the University of Alabama, was conducted at 76 centers located in 13 countries. A total of 428 patients between the ages of 22-89 with confirmed OP who had received greater than 5 mg/day of prednisone or equivalent for more than 3 months preceding screening were included. Research measures included changes in lumbar spine and hip bone, BMD, changes in bone biomarkers, fracture incidence, and safety.

Study participants were randomly assigned to receive injectable teriparatide (20 μg/day) plus oral placebo (150 subjects) or oral alendronate (10 mg/day) plus injectable placebo (144 subjects). Supplements of calcium (1,000 mg/day) and vitamin D (800 IU/day) were provided to all study participants. Subjects kept a daily journal to record their steroid use.

Results show at 36 months the BMD for lumbar spine was 11% higher than baseline in the teriparatide group compared with 5.3% in the alendronate group. The BMD (teriparatide versus alendronate) for total hip was 5.2% versus 2.7% and 6.3% versus 3.4% for femoral neck. Researchers also observed fewer vertebral fractures in subjects taking teriparatide (1.7%) than those administered alendronate (7.7%). Higher levels of calcium concentrations were noted in the teriparatide group (21%) than in the alendronate group (7%).

"There is a significant number of individuals who are regularly treated with steroids to control inflammation which puts them at risk for developing osteoporosis. A need for therapies that mitigate this side-effect of steroid use and substantially improves bone mass is vital," commented Dr. Saag. The ACR estimates that diseases commonly treated with (cortico)steroids may affect more than 30 million Americans. "Our research shows that teriparatide is a safe and effective treatment for patients with steroid-induced OA and should be considered as a therapeutic option for those at high risk of bone fracture," recommended Dr. Saag.


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. FDA Approves Expanded Use of Lillys FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis
2. Cheap, quick bedside eye movement exam outperforms MRI for diagnosing stroke in patients
3. New heart disease risk score outperforms existing test
4. Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer
5. MedAmerica Reports Solid Growth, Outperforms Industry
6. PET outperforms CT in characterization of lung nodules
7. COURAGE Sub-study: PCI Outperforms Drugs-Only
8. Watson to Distribute Alendronate Tablets
9. Stanford study recommends change in treating pulmonary embolisms
10. Oklahoma scientists discover promising new path for treating traumas
11. Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent of ... report that family members or friends have also commented about their poor hearing. ... wear hearing aids. One reason, suggested by 89 percent of American respondents, is ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued to steadily ... the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, APOP also ... the benefits of corn and grains, value of raw and organic diets, and the ...
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a home ... University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, March ... Aging is a tremendous resource in our community. We are thrilled to participate in ...
(Date:2/22/2017)... ... 22, 2017 , ... Alto-Shaam is pleased to announce an ... offers up to four ovens in one. Control temperature, fan speed and time ... in cooking. Alto-Shaam has partnered with Appliance Innovation to introduce this game-changing advancement ...
(Date:2/21/2017)... ... February 22, 2017 , ... Author Michèle Wolff has a passion for ... and family to know all about it for optimal health. Wanting to share her ... “ Detox, Digestive and Wellness Solutions ” (published by Balboa Press AU). , ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 A research report by Arcview ... and the continuously changing landscape of the legal market ... the North America , a 30% increase from ... $21.6 billion by the year 2021 representing a 26 percent compound ... United States and Canada is ...
(Date:2/22/2017)... Feb. 22, 2017  Tri-Source Pharma announced today the ... series of newly appointed positions were added to form ... Robert DiCrisci , in the implementation and administration ... of the recently consolidated subsidiary companies. ... will be composed of the following eight members reporting ...
(Date:2/22/2017)... , Feb. 22, 2017  Based on ... market, Frost & Sullivan recognizes SnooZeal, Inc. with ... is a highly innovative product that intelligently addresses ... the tongue muscles through the clinically proven continuous ... (OTC) status, SnooZeal is one of the most ...
Breaking Medicine Technology: